Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21715400 | 0.93 | NOTUM (0.42) | MAPK1HSD17B10KDM4ENOTUMUSP2 | |
| SCHEMBL6113102 | 0.85 | KDM4E (0.47) | KDM4EHPGD | |
| SCHEMBL22560166 | 0.83 | BRD4 (0.38) | — | |
| SCHEMBL30753441 | 0.83 | BRD4 (0.38) | — | |
| SCHEMBL21715385 | 0.81 | BRD4 (0.35) | KDM4EHPGD | |
| SCHEMBL6112857 | 0.81 | NOTUM (0.38) | NOTUM | |
| SCHEMBL1771400 | 0.81 | TUBB4A (0.43) | — | |
| SCHEMBL6112784 | 0.81 | DHFR (0.38) | MAPK1HSD17B10KDM4EADORA1 | |
| SCHEMBL6112836 | 0.81 | BRD4 (0.38) | — | |
| SCHEMBL21715430 | 0.80 | PDE1A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807932-B2 | Benzosuberene analogues and related compounds with activity as anticancer agents | BAYLOR UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200055805-A1 | BENZOSUBERENE ANALOGUES AND RELATED COMPOUNDS WITH ACTIVITY AS ANTICANCER AGENTS | BAYLOR UNIVERSITY (US) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055805-A1 | BENZOSUBERENE ANALOGUES AND RELATED COMPOUNDS WITH ACTIVITY AS ANTICANCER AGENTS | TUBB1, TUBB3, TUBB | MAPK1 2541/4885HSD17B10 1596/4885KDM4E 3545/4885 |
| US-10807932-B2 | Benzosuberene analogues and related compounds with activity as anticancer agents | TUBB1, TUBB3, TUBB | MAPK1 2541/4885HSD17B10 1596/4885KDM4E 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.